This cluster reflects routine option exercise and diversification activity by executives, not a signal of fundamental concern. Traders should monitor for any follow-up filings or news around earnings or pipeline updates, but no immediate action is warranted based on this activity.
ACAD drugs
ACAD drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 25 $22.01entry
- T+1 · 8mo ago −2.45%α −0.68% · $21.47
- T+5 · 8mo ago +1.41%α +1.65% · $22.32
- T+20 · 7mo ago +0.45%α −7.41% · $22.11
- T+60 · 5mo ago +0.41%α −13.05% · $22.10
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Multiple C-suite executives at Acadia Pharmaceuticals, including the CEO, CFO, and other senior officers, conducted open-market share sales totaling approximately $504,000 over a two-day period, concurrent with the exercise of stock options. The sales represent a coordinated liquidity event following derivative exercises, but the dollar amount is small relative to the company's $3.8B market cap.
Key Financial Metrics
Key Facts
- CEO Catherine Owen Adams sold $249,932 worth of shares, CFO Mark Schneyer sold $158,332, and other C-suite executives sold an additional $95,766 in open-market transactions.
- All sales were preceded by or concurrent with the exercise of stock options (M-coded transactions), indicating pre-planned option monetization rather than discretionary selling of held shares.
- Total open-market sale value across all insiders: ~$504,000 over two days.
- Total value represents only 0.013% of Acadia's $3.8B market cap, well below the 0.1% threshold for materiality.
- No negative corporate news or guidance changes were reported alongside these transactions.
Financial Impact
$504,000 in open-market sales over two days (0.013% of market cap)
Risk Factors
- Perception risk: Concentrated insider selling, even if routine, could be misinterpreted by retail investors as negative sentiment.
- Liquidity timing: If these sales were accelerated ahead of potential bad news, it could raise questions, though no such catalyst is currently evident.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (20 trades, 7d window) | cluster-ACAD-1774569644055 |
Track record
14 reports on ACAD
1 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +5.01% at T+20 after the May 6, 2026 report. 2 of 5 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $18.28 Now $18.67 +2.13% settles Dec 9
- Nov 4, 202612d ago 8-K Bullish 6/10 Entry $21.24 Now $18.67 −12.10% settles Dec 4
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $20.57 Now $18.67 −9.24% settles Dec 2
- Oct 23, 202624d ago 8-K Neutral 3/10 Entry $19.74 Now $18.67 −5.42% settles Nov 23
- Sep 24, 20267w ago 8-K Bullish 6/10 Entry $20.68 to $19.73 Now $18.67 −9.72% ▼ −4.59% −3.12% vs SPY
- Sep 11, 20269w ago 8-K Neutral 3/10 Entry $27.52 to $19.41 Now $18.67 −32.16% ▼ −29.47% −31.73% vs SPY
- Aug 16, 202613w ago Institutional Cluster Mixed 5/10 Entry $29.01 to $26.76 Now $18.67 −35.64% ▼ −7.76% −5.78% vs SPY
- Aug 7, 202614w ago Insider Cluster Neutral 2/10 Entry $29.39 to $27.58 Now $18.67 −36.47% ▼ −6.16% −5.24% vs SPY
- Jun 11, 202622w ago Institutional Cluster Bearish 6/10 Entry $21.39 to $26.41 Now $18.67 +12.72% ▼ −23.47% −21.58% vs SPY
- May 6, 202627w ago 8-K Bearish 6/10 Entry $22.56 to $21.43 Now $18.67 +17.24% ▲ +5.01% +8.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers